MetaCap

Janux Therapeutics (JANX) vs Kura Oncology (KURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kura Oncology (KURA) has outperformed Janux Therapeutics (JANX) over the past year, losing 38.1% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -50.7% for KURA. Kura Oncology is the larger company by market cap ($634.9 million vs $616.7 million), about 1.0 times the size.

Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -1136.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX-65.00%KURA-38.14%
+26%-22%-69%
Nov 21, 20251 yearNov 20, 2026
JANX-43.62%KURA-59.33%
+280%+98%-84%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus KURA key metrics
MetricJANXKURA
Share price$10.08$6.91
Market cap$616.73M$634.88M
1-day change-2.04%-5.99%
YTD return-26.96%-33.49%
1-year return-65.00%-38.14%
5-year return-42.92%-50.66%
EPS (TTM)$-1.59$-3.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.00M$67.48M
Revenue growth (YoY)-5.55%+25.24%
Net income (latest FY)$-113.63M$-278.67M
Operating margin-1576.67%-449.94%
Net margin-1136.25%-412.95%
52-week high$35.34$13.90
52-week low$10.05$6.75
Distance from 52-week high-71.48%-50.29%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+228.77%+357.60%
Average volume961.56K2.10M
Shares outstanding61.18M91.88M
Employees114260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KURA has outperformed JANX by 26.9 percentage points over the past year.
  • Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
  • Kura Oncology grew revenue faster in its latest fiscal year (+25.24% vs -5.55%).

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

JANX vs KURA FAQ

Which is bigger, Janux Therapeutics or Kura Oncology?

Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $616.73M for Janux Therapeutics (JANX).

Which stock has performed better over the past year, JANX or KURA?

KURA returned -38.14% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Janux Therapeutics and Kura Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons